CUE

Cue Biopharma, Inc. [CUE] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

CUE Stock Summary

Top 10 Correlated Stocks

CUE


In the News

08:00 28 Mar 2024 CUE

Cue Biopharma to Present at the JMP Securities Hematology and Oncology Summit

BOSTON, Nov. 22, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of T cell engagers to selectively modulate tumor-specific T cells, announced today that it will take part in a fireside chat at the JMP Securities Hematology and Oncology Summit being held virtually from December 5-6, 2023.

03:32 28 Mar 2024 CUE

Cue Biopharma, Inc. (CUE) Q3 2023 Earnings Call Transcript

Cue Biopharma, Inc. (NASDAQ:CUE ) Q3 2023 Earnings Conference Call November 9, 2023 4:30 PM ET Company Participants Daniel Passeri - CEO Matteo Levisetti - Chief Medical Officer Anish Suri - President & Chief Scientific Officer Kerri-Ann Millar - CFO Conference Call Participants Reni Benjamin - JMP Securities Ted Tenthoff - Piper Sandler Operator Good afternoon, ladies and gentlemen, and welcome to the Cue Biopharma Third Quarter 2023 Earnings Call. At this time, all lines are in listen-only mode.

08:00 28 Mar 2024 CUE

Cue Biopharma to Present at Three Upcoming Investor Healthcare Conferences in November

BOSTON, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of T cell engagers to selectively modulate tumor-specific T cells, announced today that it will participate in three investor conferences this November, the Stifel Healthcare Conference, to be held in New York from November 14-15, the Jefferies London Healthcare Conference, to be held in London from November 14-16, and the Piper Sandler Annual Healthcare Conference, to be held in New York from November 28-30.

10:23 28 Mar 2024 CUE

Cue Biopharma, Inc. (CUE) Q2 2023 Earnings Call Transcript

Cue Biopharma, Inc. (NASDAQ:CUE ) Q2 2023 Earnings Conference Call August 9, 2023 4:30 PM ET Company Participants Dan Passeri - Chief Executive Officer Anish Suri - President & Chief Scientific Officer Matteo Levisetti - Chief Medical Officer Kerri Millar - Chief Financial Officer Conference Call Participants Ted Tenthoff - Piper Sandler Ren Benjamin - JMP Securities Operator Greetings, and welcome to the Cue Biopharma Investor Update Call. At this time, all participants are in a listen-only mode.

06:40 28 Mar 2024 CUE

3 Biotech Stocks to Buy as Companies Ink Major Deals

With patent expirations around the corner, some of the biggest pharmaceutical and biotech companies will soon face generic competition, creating a big opportunity for these top biotech stocks to buy. In 2023 alone, pharmaceutical and biotech companies spent about $85 billion on acquisitions.

08:00 28 Mar 2024 CUE

Cue Biopharma to Present at the Jefferies 2023 Global Healthcare Conference

BOSTON, June 05, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient's body, announced today that it will present at the Jefferies Global Healthcare Conference being held June 7–9, 2023 in New York.

06:19 28 Mar 2024 CUE

3 Biotech Stocks Sitting on Huge-Upside Catalysts

Now is a great time to start accumulating top biotech stocks. The biotech boom is red-hot.

08:00 28 Mar 2024 CUE

Cue Biopharma to Present at the Upcoming JMP Securities Life Sciences Conference

BOSTON, May 08, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient's body, announced today that it will take part in a fireside chat at the JMP Securities Life Sciences Conference being held at the New York Hilton Midtown, May 15-16, 2023.

01:56 28 Mar 2024 CUE

7 High-Potential Penny Stocks in the Biotech Sector

Most of the biggest biotech stocks on the market started off as unknown penny stocks. Look at Axsome Therapeutics (NASDAQ: AXSM ), for example.

11:00 28 Mar 2024 CUE

Cue Biopharma, Inc. (CUE) Q4 2022 Earnings Call Transcript

Cue Biopharma, Inc. (NASDAQ:CUE ) Q4 2022 Earnings Conference Call March 21, 2023 4:30 PM ET Company Participants Dan Passeri - CEO Matteo Levisetti - Chief Medical Officer Ken Pienta - Clinical Advisory Anish Suri - President and Chief Scientific Officer Kerri Millar - CFO Sara Pai - Surgical Oncologist and Director, Translational Head and Neck Cancer Research, Mass General Hospital Conference Call Participants Ted Tenthoff - Piper Sandler Ren Benjamin - JMP Securities Mark Breidenbach - Oppenheimer Stephen Willey - Stifel Operator Greetings, and welcome to the Cue Biopharma Fourth Quarter and Full Year 2022 Earnings Call. [Operator Instructions] As a reminder, this conference is being recorded.

CUE Financial details

Company Rating
Sell
Market Cap
85.73M
Income
-51.85M
Revenue
3.82M
Book val./share
0.92
Cash/share
1.18
Dividend
-
Dividend %
-
Employees
51
Optionable
No
Shortable
Yes
Earnings
07 May 2024
P/E
-2.76
Forward P/E
-1.9
PEG
2.29
P/S
36.5
P/B
3.36
P/C
1.56
P/FCF
-3.53
Quick Ratio
3.27
Current Ratio
3.34
Debt / Equity
0.38
LT Debt / Equity
0.21
-
-
EPS (TTM)
-1.24
EPS next Y
-0.97
EPS next Q
-0.28
EPS this Y
4.96%
EPS next Y
-21.77%
EPS next 5Y
-75.4%
EPS last 5Y
-5.27%
Revenue last 5Y
1.74%
Revenue Q/Q
51.95%
EPS Q/Q
-17.24%
-
-
-
-
SMA20
-9.43%
SMA50
-34.25%
SMA100
-
Inst Own
27.83%
Inst Trans
0.9%
ROA
-75%
ROE
-99%
ROC
-1.03%
Gross Margin
100%
Oper. Margin
-1392%
Profit Margin
-1357%
Payout
-
Shs Outstand
45.12M
Shs Float
43.66M
-
-
-
-
Target Price
6.5
52W Range
1.7-5.12
52W High
-63.2%
52W Low
+84%
RSI
40.78
Rel Volume
0.62
Avg Volume
284.12K
Volume
175.42K
Perf Week
-7.54%
Perf Month
-18.94%
Perf Quarter
-14.02%
Perf Half Y
-17.49%
-
-
-
-
Beta
2.038
-
-
Volatility
0.05%, 0.14%
Prev Close
0%
Price
1.84
Change
-3.16%

CUE Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2022-12-31

Metric History 2018-12-312019-12-312020-12-312021-12-31 2022-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
0.060.160.110.480.03
Net income per share
-1.94-1.66-1.56-1.41-1.48
Operating cash flow per share
-1.31-1.4-1.13-1.24-1.17
Free cash flow per share
-1.4-1.4-1.15-1.27-1.18
Cash per share
1.952.72.962.062.14
Book value per share
1.692.482.752.091.84
Tangible book value per share
1.692.482.752.091.84
Share holders equity per share
1.692.482.752.091.84
Interest debt per share
00.260.250.320.56
Market cap
94.63M349.91M358.89M353.84M101.6M
Enterprise value
73.83M311.42M291.17M299.52M69.3M
P/E ratio
-2.43-9.53-8.01-8.01-1.92
Price to sales ratio
82.82101.19113.7823.6881.59
POCF ratio
-3.58-11.36-11.04-9.11-2.43
PFCF ratio
-3.35-11.34-10.85-8.9-2.42
P/B Ratio
2.796.414.555.41.55
PTB ratio
2.796.414.555.41.55
EV to sales
64.6290.0692.3120.0555.65
Enterprise value over EBITDA
-1.95-8.47-6.62-6.85-1.37
EV to operating cash flow
-2.8-10.11-8.96-7.71-1.66
EV to free cash flow
-2.61-10.1-8.8-7.54-1.65
Earnings yield
-0.41-0.1-0.12-0.12-0.52
Free cash flow yield
-0.3-0.09-0.09-0.11-0.41
Debt to equity
00.110.090.150.29
Debt to assets
00.080.070.120.21
Net debt to EBITDA
0.551.051.541.240.64
Current ratio
6.535.245.365.356.68
Interest coverage
0000-74.56
Income quality
0.680.840.730.880.79
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
9.893.684.641.1612.98
Research and developement to revenue
24.987.9510.632.7730.98
Intangibles to total assets
00000
Capex to operating cash flow
0.0700.020.020
Capex to revenue
-1.62-0.01-0.19-0.06-0.14
Capex to depreciation
-2.44-0.01-0.560.51-0.09
Stock based compensation to revenue
6.281.893.320.777.63
Graham number
8.579.639.838.157.84
ROIC
-1.16-0.56-0.49-0.52-0.56
Return on tangible assets
-0.86-0.51-0.45-0.53-0.58
Graham Net
1.382.292.281.561.42
Working capital
34.39M49.37M71.21M55.68M65.64M
Tangible asset value
33.97M54.57M78.91M65.49M65.68M
Net current asset value
29.22M44M66.91M50.56M51.59M
Invested capital
00.110.090.150.29
Average receivables
426.19K377.45K1.09M2.28M1.6M
Average payables
1.68M1.46M1.48M2.33M2.66M
Average inventory
112.75K7.56M7.56M0.51
Days sales outstanding
079.68164.0276.7716.78
Days payables outstanding
011.7222.53-531.84551.95
Days of inventory on hand
0200.77000
Receivables turnover
04.582.234.7521.75
Payables turnover
031.1416.2-0.690.66
Inventory turnover
01.820-1.78M1.81M
ROE
-1.15-0.67-0.57-0.67-0.8
Capex per share
-0.090-0.02-0.030

Quarterly Fundamentals Overview

Last date of statement is 2023-09-30 for Q3

Metric History 2022-09-302022-12-312023-03-312023-06-30 2023-09-30
2.02K2.02K2.02K2.02K2.02K
Revenue per share
0000.030.05
Net income per share
-0.31-0.41-0.3-0.29-0.24
Operating cash flow per share
-0.19-0.29-0.24-0.23-0.17
Free cash flow per share
-0.2-0.29-0.24-0.23-0.17
Cash per share
1.672.141.481.291.18
Book value per share
1.431.841.231.030.92
Tangible book value per share
1.431.841.231.030.92
Share holders equity per share
1.431.841.231.030.92
Interest debt per share
0.560.550.430.410.36
Market cap
78.91M101.6M159.41M163.52M106.62M
Enterprise value
68.79M69.3M121.79M128.66M68.31M
P/E ratio
-1.81-1.76-3.02-3.1-2.42
Price to sales ratio
1.16K671.84852.45118.3250.77
POCF ratio
-11.48-9.66-14.72-15.77-13.67
PFCF ratio
-11.35-9.66-14.71-15.77-13.67
P/B Ratio
1.551.552.93.552.5
PTB ratio
1.551.552.93.552.5
EV to sales
1.01K458.26651.393.132.53
Enterprise value over EBITDA
-6.68-5.07-10.27-10.63-6.93
EV to operating cash flow
-10.01-6.59-11.24-12.41-8.76
EV to free cash flow
-9.9-6.59-11.24-12.41-8.76
Earnings yield
-0.14-0.14-0.08-0.08-0.1
Free cash flow yield
-0.09-0.1-0.07-0.06-0.07
Debt to equity
0.390.290.340.390.38
Debt to assets
0.260.210.230.250.24
Net debt to EBITDA
0.982.363.172.883.88
Current ratio
6.046.684.983.743.34
Interest coverage
-88.96-41.43-36.16-58.26-39.93
Income quality
0.630.720.830.790.71
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
51.8824.4922.333.071.74
Research and developement to revenue
111.3474.9350.227.714.7
Intangibles to total assets
00000
Capex to operating cash flow
0.010000
Capex to revenue
-1.150-0.0100
Capex to depreciation
-0.140000
Stock based compensation to revenue
30.3513.9610.681.470.99
Graham number
3.154.12.862.612.22
ROIC
-0.14-0.16-0.16-0.2-0.18
Return on tangible assets
-0.14-0.16-0.16-0.18-0.16
Graham Net
0.971.420.890.70.64
Working capital
51.48M65.64M54.95M44.63M40.31M
Tangible asset value
50.76M65.68M55.02M46M42.67M
Net current asset value
36.16M51.59M42.09M33.78M31.3M
Invested capital
0.390.290.340.390.38
Average receivables
766K426.63K126.63K665.5K1.4M
Average payables
1.81M2.39M2.44M2.25M2.42M
Average inventory
00.5110.5
Days sales outstanding
1.05K34.0794.3373.9171.19
Days payables outstanding
341.47423.75219.99250.05260.44
Days of inventory on hand
00000
Receivables turnover
0.092.640.951.221.26
Payables turnover
0.260.210.410.360.35
Inventory turnover
0580.06K880K848K0
ROE
-0.21-0.22-0.24-0.29-0.26
Capex per share
00000

CUE Frequently Asked Questions

What is Cue Biopharma, Inc. stock symbol ?

Cue Biopharma, Inc. is a US stock , located in Cambridge of Ma and trading under the symbol CUE

Is Cue Biopharma, Inc. buy or a sell ?

2 stock analysts have 2 predictions with a medium analyst target price of $6.5. The lowest prediction is $6 and the highest is $7

What is CUE stock prediction ?

With a median analyst target price of $6, 1 stock analysts have made 1 forecasts in last 90 days. $6 is the lowest and $6 is the greatest projection.

What is Cue Biopharma, Inc. stock quote today ?

Cue Biopharma, Inc. stock price is $1.84 today.

Is Cue Biopharma, Inc. stock public?

Yes, Cue Biopharma, Inc. is a publicly traded company.

Something similar

Top by Market Cap
Top Correlated Stocks
Similar Market Cap